- Home
- MARA vs IONS Comparison
MARA vs IONS Comparison
Compare MARA & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MARA
- IONS
- Stock Information
- Founded
- MARA 2010
- IONS 1989
- Country
- MARA United States
- IONS United States
- Employees
- MARA N/A
- IONS N/A
- Industry
- MARA EDP Services
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- MARA Technology
- IONS Health Care
- Exchange
- MARA Nasdaq
- IONS Nasdaq
- Market Cap
- MARA 5.1B
- IONS 6.0B
- IPO Year
- MARA N/A
- IONS 1991
- Fundamental
- Price
- MARA $24.18
- IONS $33.94
- Analyst Decision
- MARA Buy
- IONS Buy
- Analyst Count
- MARA 8
- IONS 18
- Target Price
- MARA $22.57
- IONS $62.00
- AVG Volume (30 Days)
- MARA 70.4M
- IONS 1.2M
- Earning Date
- MARA 11-12-2024
- IONS 11-06-2024
- Dividend Yield
- MARA N/A
- IONS N/A
- EPS Growth
- MARA N/A
- IONS N/A
- EPS
- MARA 0.62
- IONS N/A
- Revenue
- MARA $598,752,000.00
- IONS $803,067,000.00
- Revenue This Year
- MARA $75.94
- IONS N/A
- Revenue Next Year
- MARA $36.98
- IONS $16.31
- P/E Ratio
- MARA $38.97
- IONS N/A
- Revenue Growth
- MARA 131.04
- IONS 30.57
- 52 Week Low
- MARA $10.76
- IONS $33.33
- 52 Week High
- MARA $34.09
- IONS $54.44
- Technical
- Relative Strength Index (RSI)
- MARA 62.33
- IONS 32.44
- Support Level
- MARA $17.72
- IONS $33.33
- Resistance Level
- MARA $26.19
- IONS $40.07
- Average True Range (ATR)
- MARA 2.27
- IONS 1.54
- MACD
- MARA 0.23
- IONS -0.39
- Stochastic Oscillator
- MARA 81.53
- IONS 9.05
About MARA Marathon Digital Holdings Inc.
Marathon Digital Holdings Inc focuses on mining digital assets. It owns crypto-currency mining machines and a data center to mine digital assets. The company currently operates in the Digital Currency Blockchain segment. The Crypto-currency Machines are located in the United States.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.